FUS Phase Separation in Neurodegeneration describes the molecular cascade from normal FUS RNA-binding protein function through liquid-liquid phase separation (LLPS) to pathological aggregation in amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD). FUS (Fused in Sarcoma, also known as TLS) is a member of the FET (FUS, EWS, TAF15) family of RNA-binding proteins crucial for RNA metabolism. Disease-causing mutations induce a liquid-to-solid phase transition that drives neurodegeneration.
This mechanism page comprehensively covers: (1) FUS domain architecture and normal function, (2) the biophysics of liquid-liquid phase separation, (3) stress granule dynamics, (4) pathogenic phase transitions, and (5) therapeutic targeting strategies.
¶ FUS Domain Architecture
FUS is a 526-amino acid RNA-binding protein encoded by the FUS gene on chromosome 16p11.2. The protein contains several distinct domains[@law2010]:
N-terminal Low-Complexity Domain (LCD, residues 1-214):
- Prion-like domain enriched in glycine, glutamine, asparagine, tyrosine, and serine
- Contains multiple phosphorylation sites
- Drives liquid-liquid phase separation
- Contains the prion-like domain critical for aggregation
RNA Recognition Motifs (RRM1 and RRM2, residues 260-380):
- Classical RRM fold for RNA binding
- Recognize GU-rich sequence motifs
- Also contribute to protein-protein interactions
Zinc Finger Domain (ZF, residues 382-421):
- Cys2His2-type zinc finger
- Enhances RNA binding
- Contributes to nuclear localization
C-terminal Nuclear Localization Signal (NLS, residues 498-526):
- PY motif (Pro-Tyr) for nuclear import
- Binds transportin-1 (karyopherin-β2)
- Site of multiple ALS-causing mutations
flowchart LR
subgraph FUS_Domain_Structure
A["N-LCD<br>1-214"] --> B["RRM1<br>260-300"]
B --> C["RRM2<br>300-380"]
C --> D["Zinc Finger<br>382-421"]
D --> E["C-Terminal<br>422-526"]
end
A -->|"LLPS"| F["Phase Separation"]
D -->|"NLS"| G["Nuclear Import"]
In the nucleus, FUS participates in essential RNA metabolism[@blasco2022]:
1. Transcriptional Regulation
- Interacts with RNA polymerase II
- Co-activates transcription
- Regulates gene expression programs
2. Alternative Splicing
- Binds to pre-mRNA transcripts
- Regulates splice site selection
- Particularly important for neuronal transcripts
3. RNA Processing
- mRNA 3'-end processing
- RNA transport from nucleus
- RNA stability regulation
4. DNA Damage Response
- Recruitment to DNA damage sites
- Facilitates repair machinery
- Links transcription to DNA repair
FUS also functions in the cytoplasm:
1. RNA Transport
- Localizes to neuronal processes
- Transports mRNAs to synapses
- Regulates local translation
2. Stress Response
-Incorporates into stress granules
- Participates in stress response
- Protects mRNAs during stress
Liquid-liquid phase separation (LLPS) is a fundamental biophysical process by which proteins and nucleic acids form condensed liquid-like droplets without a membrane[@zhang2019]. FUS undergoes LLPS through its low-complexity domain:
1. Multivalent Interactions
- Multiple weak interaction sites in LCD
- π-π stacking between aromatic residues
- Cation-π interactions with RNA
2. RNA-Mediated Crosslinking
- FUS binding to RNA increases valency
- RNA acts as scaffolding
- Formaldehyde crosslinking enhances droplet formation
3. Concentration Dependence
- LLPS occurs above a threshold concentration
- In vitro: ~1-5 μM FUS
- Cellular concentration approaches this threshold
Normal LLPS is tightly regulated:
Physiological Regulators:
- Post-translational modifications (phosphorylation)
- RNA-to-protein ratio
- Molecular crowding
- Ionic conditions
Stress-Induced Changes:
- Stress triggers FUS relocalization
- SG components increase local concentration
- LLPS is enhanced
flowchart TD
A["FUS Protein"] --> B["RNA Binding"]
B --> C["Multivalent Interactions"]
C --> D["Liquid-Liquid Phase Separation"]
D --> E["Dynamic Liquid Droplets"]
E --> F["Stress Resolution"]
F --> G["Normal Function"]
D --> H["Pathological Trigger"]
H --> I["Increased Viscosity"]
I --> J["Gelation"]
J --> K["Solid Aggregation"]
FUS is a canonical stress granule component[@dormann2010]. Under stress conditions:
1. Recruitment to Stress Granules
- Stress triggers phosphorylation of eIF2α
- Global translation is attenuated
- FUS is recruited to SGs
2. Dynamic Exchange
- FUS freely exchanges in normal SGs
- Liquid-like behavior is maintained
- Return to normal upon stress resolution
3. Physiological Role
- Protects specific mRNAs
- Enables stress recovery
- Facilitates translation restart
ALS-associated FUS mutations dramatically alter SG dynamics[@dormann2010]:
1. Enhanced SG Recruitment
- Mutant FUS shows increased SG partitioning
- Mutations accelerate recruitment
- More FUS is retained in SGs
2. Delayed Disassembly
- Mutant FUS delays SG dissolution
- SG persistence is prolonged
- Recovery from stress is impaired
3. Altered Material Properties
- Droplet viscosity is increased
- Dynamics are slowed
- Liquid-to-solid transition is favored
The critical pathogenic event is the liquid-to-solid phase transition induced by ALS mutations[@murakami2015]:
Molecular Mechanism:
- Mutations in the low-complexity domain
- Alteration of interaction surfaces
- Increased propensity for β-sheet formation
- Stable fibril formation
Key Mutations:
- P525L: Most aggressive, juvenile-onset
- R521C: Most common adult-onset
- R522G, R514P, R521H
Consequences:
- Loss of droplet dynamics
- Irreversible aggregation
- Sequestration of normal proteins
Beyond gelation, FUS can form amyloid-like fibrils[@shenoy2023]:
Fibril Structure:
- Cross-β sheet architecture
- Similar to amyloid fibrils
- Detectable by cryo-EM
Template-Directed Aggregation:
- FUS fibrils can template normal FUS
- Prion-like propagation
- Intercellular spread
flowchart TD
A["FUS Mutation<br>P525L, R521C"] --> B["Altered LCD Interactions"]
B --> C["Increased Aggregation Propensity"]
C --> D["Liquid-Liquid Phase Separation"]
D --> E["Pathological LLPS"]
E --> F["Increased Viscosity"]
F --> G["Gelation"]
G --> H["Solid Fibrils"]
H --> I["Cytoplasmic Inclusions"]
I --> J["Neuronal Dysfunction"]
J --> K["Motor Neuron Degeneration"]
K --> L["ALS Phenotype"]
The C-terminal NLS of FUS binds transportin-1 (also called karyopherin-β2) for nuclear import[@butta2020]:
Normal Import:
- FUS NLS binds transportin-1
- Cargo complex translocates through nuclear pore
- FUS enters the nucleus
Mutant Import:
- Most ALS mutations cluster in the NLS
- P525L disrupts transportin-1 binding
- Nuclear import is impaired
Impaired nuclear import leads to cytoplasmic accumulation:
Consequences:
- Cytoplasmic FUS is recruited to SGs
- Normal nuclear function is lost
- Cytoplasmic gain-of-function occurs
Therapeutic Target:
-Transportin-1 modulators
| Target |
Strategy |
Status |
| FUS expression |
ASO silencing |
Preclinical |
| Phase separation |
LLPS modulators |
Research |
| Nuclear import |
Transportin-1 modulators |
Research |
| Aggregation |
Small molecules |
Preclinical |
| Clearance |
Autophagy enhancers |
Preclinical |
| Neuroprotection |
Antioxidants, mitochondrial protectants |
Preclinical |
Phase Separation Modulators:
- Target LLPS dynamics
- Prevent liquid-to-solid transition
- Modulate viscosity
Aggregation Inhibitors:
- Prevent fibril formation
- Disrupt existing aggregates
- Promote clearance
Nuclear Import Enhancers:
- Increase transportin-1 function
- Enhance nuclear localization
ASO-Mediated Silencing:
- Reduce mutant FUS expression
- Allele-specific approaches possible
- Viral delivery under development
CRISPR-Based Editing:
- Correct mutations
- Allele-specific targeting
- Promising but in early stages
FUS inclusions are cleared via selective autophagy:
p62/SQSTM1-Mediated:
- Recognizes ubiquitinated FUS
- Targets to autophagosomes
- Lysosomal degradation
OPTN-Mediated:
- OPTN serves as receptor
- TBK1 phosphorylates OPTN
- Both ALS-linked proteins
Autophagy enhancement promotes clearance:
- mTOR inhibitors (rapamycin, torin1)
- TFEB activators (trehalose)
- Autophagy gene therapy
- Younger age of onset (often <40 years)
- Rapid progression
- Predominant bulbar involvement
- Prominent upper motor neuron signs
- Cognitive/behavioral changes in some cases
- Neurofilament light chain (NfL): Elevated, disease progression
- FUS in CSF: Potential biomarker
- Genetic testing: Identifies pathogenic mutations
- Neuroimaging: Corticospinal tract abnormalities
- Law WJ, et al, TLS, FUS, EWS and TAF15: a novel group of nuclear RNA-binding proteins (2010)
- Zhang L, et al, Role of the low complexity domain in FUS phase separation (2019)
- Murakami T, et al, ALS/FTD mutations induce a liquid-to-solid phase transition (2015)
- Dormann D, et al, ALS-associated FUS mutations disrupt stress granule dynamics (2010)
- Butler M, et al, FUS-mediated nuclear transport in ALS pathogenesis (2020)
- Gasset-Rosa F, et al, Targeting phase separation as therapeutic strategy in ALS/FTD (2024)
- Houston BJ, et al, FUS is phosphorylated by DNA-dependent protein kinase (2018)
- Sidhu H, et al, FUS, TDP-43 and the cellular stress response in ALS/FTD (2014)
- Blasco H, et al, FUS-regulated RNA metabolism in ALS pathogenesis (2022)
- Shenoy J, et al, FUS aggregates: From liquid-liquid phase separation to amyloid fibrils (2023)
- Singh V, et al, FUS phase separation and aggregation in neurodegeneration (2024)